Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AcruxASX:ACR +5.00% Days Sales Outstanding is 71.92 as of Jun. 2026, which is 16% above its 10-year median of 61.82. The stock has 4 warning signs investors should review. Among 839 Biotechnology companies, Acrux ranks worse than 56.38% on this metric.
Acrux's average Accounts Receivable for the
six
months ended in Jun. 2026 was A$1.01 Mil. Acrux's Revenue for the
six
months ended in Jun. 2026 was A$2.56 Mil.
Hence, Acrux's Days Sales Outstanding for the
six
months ended in Jun. 2026 was 71.92.
The historical rank and industry rank for Acrux's Days Sales Outstanding or its related term are showing as below:
ASX:ACR'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 13.94 Med: 61.82 Max: 383.2
Current: 77.42
During the past 13 years, Acrux's highest Days Sales Outstanding was 383.20. The lowest was 13.94. And the median was 61.82.
ASX:ACR's Days Sales Outstanding is ranked worse than 56.38% of 839
companies
in the Biotechnology industry
Industry Median: 68.64
vs ASX:ACR: 77.42
Acrux's Days Sales Outstanding
declined
from Jun. 2025 (179.00) to Jun. 2026 (71.92).
Acrux (ASX:ACR) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Acrux Days Sales Outstanding Related Terms
Acrux Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Acrux's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:ACR vs VRTX, REGN, RVMD: Days Sales Outstanding Comparison
For the Biotechnology subindustry, Acrux's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Acrux Days Sales Outstanding vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Acrux's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Acrux's Days Sales Outstanding falls into.
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Acrux (ASX:ACR) has a Days Sales Outstanding of 71.92 as of Jun. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Acrux and its competitors. This is 16% above median its historical median of 61.82. Over the past decade, Acrux's Days Sales Outstanding has ranged from 13.94 to 383.20. According to the industry distribution chart, Acrux ranks #473 out of 839 companies in the Biotechnology industry, placing it in the top 56.4%.
Is Acrux's Days Sales Outstanding too high?
Acrux's current Days Sales Outstanding of 71.92 is 16% above median its 10-year median of 61.82. Over the past 10 years, this metric has ranged from a low of 13.94 to a high of 383.20. The Biotechnology industry median Days Sales Outstanding is 68.64. Acrux's value of 71.92 is 4.8% above this industry median. Based on the distribution chart, Acrux ranks #473 out of 839 companies in the Biotechnology industry, which is below the industry midpoint.
How does Acrux's Days Sales Outstanding compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Acrux ranks #473 out of 839 companies for Days Sales Outstanding. This places Acrux in the lower half of its industry. The industry median Days Sales Outstanding is 68.64. Acrux's value of 71.92 is 4.8% above this benchmark. Historically, Acrux's own Days Sales Outstanding has ranged from 13.94 to 383.20 over the past decade. While the company's 10-year median is 61.82 vs. the industry median of 68.64, Acrux has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Biotechnology company?
The median Days Sales Outstanding among Biotechnology companies is 68.64, based on 839 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Acrux's current Days Sales Outstanding of 71.92 is 4.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Acrux and its competitors. For the Biotechnology industry, the median Days Sales Outstanding is 68.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Acrux's current Days Sales Outstanding is 71.92, which is 16% above median its own 10-year median of 61.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Acrux stock overvalued right now?
Based on GuruFocus' analysis, Acrux (ASX:ACR) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.02, compared to a current price of A$0.01 — trading 47.5% below its estimated fair value. The current Days Sales Outstanding is 71.92, which is 16% above median its 10-year median of 61.82 and 4.8% above the Biotechnology industry median of 68.64. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Acrux (ASX:ACR), the current Days Sales Outstanding is 71.92 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Acrux Ltd is a dynamic Australian drug delivery specialist with expertise in developing and commercialising patient-preferred healthcare products for world-wide markets. Its talent creates value through the development and commercialisation of healthcare products using owned or acquired technologies. The group's products are patient preferred, protected by patent or other means, and use creative drug delivery.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:ACR has been successfully added to your 
